ACTRN12623000290695招募中未知
Prospective Validation of 18F-FDG Whole Body PET/CT as a Diagnostic Test for Polymyalgia Rheumatica
Rheumatology Clinical Trials, Austin Health0 个研究点目标入组 60 人开始时间: 2023年3月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •Suspected new diagnosis of PMR as determined by age at symptom onset greater than or equal to 50 years, bilateral shoulder aching, and elevated CRP and/or ESR (in line with 2012 EULAR/ACR Classification Criteria).
排除标准
- •- Inability to provide informed consent.
- •- Patients with symptoms suggestive of giant cell arteritis (headache, jaw claudication, scalp tenderness and/or visual disturbance).
- •- Patients with active infection.
- •- Patients with recent malignancy.
- •- Patients with established inflammatory rheumatic diseases (e.g. RA).
- •- Patients with uncontrolled diabetes (due to inability to accurately interpret 18F-FDG uptake).
- •- Patients who have been treated with glucocorticoids for greater than 7 days prior to screening, a single dose of prednisolone greater than or equal to 30mg/day and concomitant DMARD therapy.
研究者
相似试验
已完成
Unknown
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165
已完成
不适用
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.lung cancerNL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50
进行中（未招募）
1 期
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10
已完成
不适用
Evaluation of early prediction using 18F-FDG PET/CT for patients with Iodine-131 refractory differentiated thyroid carcinoma treated with lenvatinibdifferentiated thyroid carcinomaJPRN-UMIN000022592Department of Medical Oncology, Hokkaido University Graduate School of Medicine22
尚未招募
不适用
Management and prognosis of breast cancer through FDG PET/CTCTRI/2012/09/002966ot applicable Thesis Protocol500